Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First Measurement of Time-Dependent CP Violation in the Flavor-Changing Neutral-Current Decay B^{0}→K_{S}^{0}μ^{+}μ^{-}.

Physical review letters·2026
Same author

Measurement of the Top-Quark Production Cross Section and Charge Asymmetry at LHCb.

Physical review letters·2026
Same author

Searches for B^{0}→K^{+}π^{-}τ^{+}τ^{-} and B_{s}^{0}→K^{+}K^{-}τ^{+}τ^{-} Decays.

Physical review letters·2026
Same author

First Evidence of the B_{s}^{0}→K^{-}π^{+}γ Decay.

Physical review letters·2026
Same author

Precision Measurement of CP Violation and Branching Fractions in B^{±}→K_{S}^{0}h^{±} (h=π, K) Decays and Search for the Rare Decay B_{c}^{±}→K_{S}^{0}K^{±}.

Physical review letters·2026
Same author

First Observation of the B[over ¯]_{s}^{0}→Λ_{c}^{+}Λ[over ¯]_{c}^{-} Decay and Evidence for the B[over ¯]^{0}→Λ_{c}^{+}Λ[over ¯]_{c}^{-} Decay.

Physical review letters·2026
Same journal

Mechanistic factors of cardiovascular diseases.

Minerva cardioangiologica·2020
Same journal

Robotic-assisted coronary artery bypass grafting: current knowledge and future perspectives.

Minerva cardioangiologica·2020
Same journal

Features of degenerative mitral valve prolapse in the North East of China: repair characteristics, and short-term follow-up results.

Minerva cardioangiologica·2020
Same journal

Myocardial revascularization in chronic coronary syndromes: does viability matter?

Minerva cardioangiologica·2020
Same journal

Extracorporeal membrane oxygenation for COVID-19: effective weapon or futile effort?

Minerva cardioangiologica·2020
Same journal

Heart and endurance sports: excesses are often unhealthy.

Minerva cardioangiologica·2020
See all related articles

Related Experiment Video

Updated: May 11, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Recent developments in renal denervation.

C E Raphael1, J E Davies

  • 1International Centre for Circulatory Health, Imperial College, London, UK. Claire.raphael@gmail.com

Minerva Cardioangiologica
|May 18, 2013
PubMed
Summary
This summary is machine-generated.

Renal denervation, a catheter-based procedure, effectively lowers blood pressure in resistant hypertension. This innovative therapy also shows promise for treating heart failure by modulating sympathetic overactivation.

More Related Videos

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

Related Experiment Videos

Last Updated: May 11, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

Area of Science:

  • Cardiology
  • Nephrology
  • Interventional Radiology

Background:

  • Resistant hypertension poses a significant clinical challenge.
  • Sympathetic nervous system overactivity contributes to various cardiovascular diseases.
  • Novel therapeutic approaches are needed to manage complex hypertension and heart failure.

Purpose of the Study:

  • To evaluate the efficacy of renal denervation in patients with resistant hypertension.
  • To explore the potential of renal denervation in treating sympathetic overactivation in chronic systolic heart failure.
  • To assess additional benefits of renal denervation beyond blood pressure reduction.

Main Methods:

  • Renal denervation utilizes electrode-tipped catheters to deliver radiofrequency energy.
  • The therapy targets sympathetic nerves adjacent to the renal artery lumen.
  • The procedure is catheter-based, offering a minimally invasive approach.

Main Results:

  • Renal denervation has demonstrated effectiveness in lowering blood pressure in resistant hypertension.
  • Preliminary studies suggest improvements in insulin sensitivity, sleep apnea, and arrhythmias.
  • The therapy has been successfully applied to patients with chronic systolic heart failure.

Conclusions:

  • Renal denervation is a promising treatment for resistant hypertension.
  • The therapy shows potential for managing sympathetic overactivation in heart failure.
  • Ongoing trials are investigating broader applications of renal denervation in various disease states.